- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02172781
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
A Double-blind, Randomised, Two-way Cross-over Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of a Single Additional Dose of 500 µg Ipratropium Bromide Unit Dose Vial Inhaled Via Nebuliser Versus Placebo After 19 Days of Treatment With Tiotropium Inhalation Capsules 18 µg q.d. in Male Healthy Volunteers.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All participants in the study should be healthy males, ranging from 40 to 65 years of age and within ±20% of their normal weight (Broca-Index)
Each subject will have his medical history taken and will receive a complete medical examination (including blood pressure and pulse rate measurements) as well as a 12-lead ECG.
Haematological, hepatic and renal function tests will be carried out in the laboratory (Bioscentia GmbH, FRG). The subjects will fast for 8 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first drug administration.
In accordance with Good Clinical Practice (GCP) and local legislation all subjects will have given their written informed consent prior to admission to the study.
Following inclusion criteria were of special interest for this study:
- Normal spirometry as evidenced by a baseline FEV1 ≥ 80% of predicted normal value for age, height and sex. Predicted normal values will be calculated according to European Community of Coal and Steel (ECCS)
- Ability to perform technically satisfactory pulmonary function tests.
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections.
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator.
- Intake of drugs with a long half-life (≥ 24hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study.
- Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study, among these all non-selective beta blockers, oral beta adrenergics or long-acting beta-adrenergics such as salmeterol and formoterol, and anticholinergic drugs including ATROVENT ®(ipratropium) by oral inhalation and ATROVENT® Nasal Spray.
- Participation in another trial with an investigational drug (≤ two months prior to administration or during trial).
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on trial days.
- Alcohol abuse (> 60g/day)
- Drug abuse
- Blood donation (≥ 100 ml within four weeks prior to administration or during the trial)
- Any laboratory value outside the clinically accepted reference range.
- Excessive physical activities (within the last week before and during the study)
Following exclusion criteria are of special interest for the study:
- Subjects with known hypersensitivity to anticholinergic drugs.
- Subjects with known symptomatic prostatic hypertrophy or bladder neck obstruction
- Subjects with known narrow-angle glaucoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ipratropium - unit dose vial
|
|
Experimental: Tiotropium - inhalation capsule - low dose
|
|
Placebo Comparator: Placebo matching tiotropium - inhalation capsule
|
|
Placebo Comparator: Placebo matching to ipratropium - unit dose vial
|
|
Experimental: Tiotropium - inhalation capsule - high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC - Area under the curve of the log-transformed value of salivary secretion after application of randomised treatment
Time Frame: over the interval from two hours to six hours on study day 19 and 22
|
over the interval from two hours to six hours on study day 19 and 22
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (Peak (maximum) plasma concentration) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Cmax,ss (maximum observed concentration of the analyte in plasma at steady state) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Tmax (time to reach the peak plasma concentration) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Tmax, ss (Time to reach maximum concentration of the analyte in plasma at steady state) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Cpre (predose concentration of the analyte in plasma) -Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Cpre,ss (predose concentration of the analyte in plasma at steady state) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
AUC (area under the concentration time curve of the analyte in plasma) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
AUC,ss (area under the concentration time curve of the analyte in plasma at steady state) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Ae (amount of analyte that is eliminated in urine) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
CLR (renal clearance of the analyte) - Tiotropium
Time Frame: Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing)
|
Cmax (Peak (maximum) plasma concentration) - Ipratropium
Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Tmax (time to reach the peak plasma concentration) - Ipratropium
Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
AUC (area under the concentration time curve of the analyte in plasma) - Ipratropium
Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Ae (amount of analyte that is eliminated in urine) - Ipratropium
Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
CLR (renal clearance of the analyte) - Ipratropium
Time Frame: Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing)
|
Amount of Salivary secretion
Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
FEV1 (Forced expiratory volume in one second)
Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
FVC (Forced vital capacity)
Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
MMEF25-75% (maximal mid-expiratory flow)
Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
PEFR (peak expiratory flow rate)
Time Frame: Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23
|
Occurence of adverse events
Time Frame: Screening, A1-A6, B1-B23, end of study (within 8 days after last dosing tiotropium)
|
Screening, A1-A6, B1-B23, end of study (within 8 days after last dosing tiotropium)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Tiotropium Bromide
- Ipratropium
Other Study ID Numbers
- 205.239
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Ipratropium - unit dose vial
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
VA Eastern Colorado Health Care SystemUnited States Department of DefenseCompletedSuicide, Attempted | Medication Adherence | Accidental Overdose | Deliberate OverdoseUnited States
-
National Taiwan University HospitalCompleted
-
S.Biomedics Co., Ltd.Dt&SanomedicsActive, not recruitingCritical Limb IschemiaKorea, Republic of
-
University of SaskatchewanCompleted
-
Neutec Ar-Ge San ve Tic A.ŞActive, not recruiting
-
Santen SASRecruiting